Equillium To Be Included In The Russell Microcap Index, Effective At The Open Of Equity Markets On Monday, July 1

6/12/24 8:10:10 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EQ alert in real time by email

Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.

Get the next $EQ alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EQ

Date	Price Target	Rating	Analyst
1/5/2022	$18.00 → $14.00	Outperform	SVB Leerink
10/29/2021	$12.00	Buy	Stifel
9/15/2021	$14.00	Overweight	Cantor Fitzgerald

More analyst ratings

Equillium Maintains Rights to Itolizumab Following Ono Partnership
Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab
10/31/24 7:00:00 AM ET
$EQ
Biotechnology: Pharmaceutical Preparations
Health Care
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to
12/6/22 7:00:00 AM ET
$EQ
Biotechnology: Pharmaceutical Preparations
Health Care
Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis
Itolizumab demonstrates clinically meaningful response in highly proteinuric subjects: 5 of 6 (83%) subjects achieved complete or partial response and 4 of 6 (67%) subjects achieved > 80% reduction in urine protein creatinine ratio (UPCR) by week 28 8 of 12 (67%) subjects achieved > 50% reduction in UPCR (6 subjects still dosing) Itolizumab continues to demonstrate favorable safety and tolerability through six months of treatment Management will host a conference call and webcast today at 8:00 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical ne
9/27/22 7:00:00 AM ET
$EQ
Biotechnology: Pharmaceutical Preparations
Health Care

Equillium to be included in the Russell Microcap® Index
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and va
6/12/24 8:00:00 AM ET
$EQ
Biotechnology: Pharmaceutical Preparations
Health Care
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors
-Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in
10/23/23 8:00:00 AM ET
$CSTL
$EQ
$ICPT
Medical Specialities
Health Care
Biotechnology: Pharmaceutical Preparations
Equillium Announces Appointment of Barbara Troupin to Board of Directors
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the appointment of Barbara Troupin, M.D., to the Equillium Board of Directors. Dr. Troupin will serve as a member of the Nominating and Corporate Governance Committee of the Board. "We are very happy to welcome Dr. Barbara Troupin to the Equillium Board," said Dan Bradbury, chairman of the board of directors of Equillium. "Her experience building and leading clinical development, medical and regulatory affairs functions, as well as her background in global strategy and medical and com
3/1/22 8:00:00 AM ET
$EQ
Biotechnology: Pharmaceutical Preparations
Health Care

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
Equillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3 EQUATOR study in aGVHD to completion in Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided corporate and clinical updates. "At the end of October we announced that our partnership with Ono Pharmaceutical had ended following substantial non-dilutive fina
11/13/24 4:01:00 PM ET
$EQ
Biotechnology: Pharmaceutical Preparations
Health Care
Equillium to Present at the Stifel Healthcare Conference
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Stifel Healthcare Conference taking place in New York on November 18 & 19, 2024. Management will provide an overview of the Company's clinical programs, currently focused on the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD) and the Phase 2 study of itolizumab in ulcerative colitis. Management will be available for one-on-one meetings during the conference. Conference: Stifel Healthcare Conference
11/13/24 8:00:00 AM ET
$EQ
Biotechnology: Pharmaceutical Preparations
Health Care
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
Dual and synergistic signaling of IL-15 and IL-21 robustly augments NK and CD8 T cell responses Highlights importance of dual inhibition or activation for therapeutic approaches Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented over the weekend at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The conference took place at the George R. Brown Convention Center in Houston, Texas from November 6 to 10, 2024. "These data provide deeper insights into the dual and synergistic si
11/12/24 8:00:00 AM ET
$EQ
Biotechnology: Pharmaceutical Preparations
Health Care

Equillium To Be Included In The Russell Microcap Index, Effective At The Open Of Equity Markets On Monday, July 1

Chat with this insight

Recent Analyst Ratings for $EQ

$EQ Market Insights

Live Market Insights

Equillium Inc: Receives Nasdaq Notice Of Non-Compliance With Listing Rule 5550(A)(2) On July 19, 2024

Equillium Announces Q2 2024 Ending Cash, Cash Equivalents, And Short-Term Investments Total Approximately $33.3M, Up $1.0M From Q1; Increase Driven By $2.7M Australian Tax Credit For 2023 R&D Expenses

Equillium To Be Included In The Russell Microcap Index, Effective At The Open Of Equity Markets On Monday, July 1

$EQ Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SVB Leerink reiterated coverage on Equillium with a new price target

Stifel resumed coverage on Equillium with a new price target

Cantor Fitzgerald initiated coverage on Equillium with a new price target

$EQ Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Equillium Inc.

SEC Form SC 13G filed by Equillium Inc.

SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

$EQ Financials

Live finance-specific insights

$EQ Leadership Updates

Live Leadership Updates

$EQ Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$EQ Press Releases

Fastest customizable press release news feed in the world

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis

Equillium to be included in the Russell Microcap® Index

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Equillium Announces Appointment of Barbara Troupin to Board of Directors

Chief Financial Officer Keyes Jason A sold $7,000 worth of shares (10,000 units at $0.70) (SEC Form 4)

Sr. Vice President and COO Zedelmayer Christine sold $18,750 worth of shares (15,000 units at $1.25), decreasing direct ownership by 10% to 135,246 units (SEC Form 4)

Principal Accounting Officer Tom Penny sold $4,398 worth of shares (3,518 units at $1.25), decreasing direct ownership by 35% to 6,533 units (SEC Form 4)

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium to Present at the Stifel Healthcare Conference

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

$EQ SEC Filings

SEC Form 144 filed by Equillium Inc.

SEC Form 10-Q filed by Equillium Inc.

Equillium Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Recent Analyst Ratings for
$EQ

$EQ
Market Insights

$EQ
Analyst Ratings

$EQ
Large Ownership Changes

$EQ
Financials

$EQ
Leadership Updates

$EQ
Insider Trading

$EQ
Press Releases

$EQ
SEC Filings